Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies.

Reiter, Alfred; Schrappe, Martin; Tiemann, Markus; Parwaresch, Reza; Zimmermann, Martin; Yakisan, Elif; Dopfer, R.; Bucsky, Peter; Mann, Georg; Gadner, Helmut

doi:10.1200/jco.1994.12.5.899

Cited by 188 publications

(126 citation statements)

References 37 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…94,[245][246][247] It has been suggested that LyP is a precursor lesion of primary cutaneous ALCL. The studies summarized in Table 12 indicate that the t(2;5) NPM-ALK is Leukemia absent in LyP (except for one study) and rare in most studies on primary cutaneous CD30 + ALCL.…”

Section: Incidence Of Npm-alk In Primary Cutaneous Alcl and Lymphomatmentioning

confidence: 99%

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

et al. 2000

View full text Add to dashboard Cite

Section: Incidence Of Npm-alk In Primary Cutaneous Alcl and Lymphomatmentioning

confidence: 99%

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

et al. 2000

View full text Add to dashboard Cite

“…[10][11][12][13] The prognosis for advanced stage disease has also improved and varies based on subtype (60-90% 5-year EFS). 11,[13][14][15][16][17][18][19][20][21][22] HD Patients with HD commonly present with cervical or supraclavicular lymphadenopathy and most will present with some degree of mediastinal involvement. Current treatment involves the use of combined chemotherapy with or without low-dose involved field radiation therapy.…”

Section: Nhlmentioning

confidence: 99%

Stem cell transplantation for pediatric lymphoma: past, present and future

Bradley

Cairo

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Lymphoma is the third most common cancer in children p15 years of age. The prognosis for children with newly diagnosed chemosensitive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) has improved significantly. However, in children with relapsed and refractory NHL, the prognosis is not as promising and the best treatment approach for this poor risk group continues to be a challenge. Between 25 and 30% of patients with advanced stage HD still relapse and in subsets of this group, the outcome is dismal. Aggressive chemotherapy followed by autologous bone marrow transplantation has been used with some improvement in survival. Some centers have investigated allogeneic stem cell transplantation in pediatric patients with recurrent/relapsed lymphoma. There is little consistency in therapeutic approaches and there is no formal recommendation on the best approach for this poor prognostic subgroup. We illustrate the reported pediatric experience of transplantation for lymphoma and discuss how the results from these trials are influencing how we approach the treatment in certain subgroups of pediatric patients with relapsed/ refractory lymphoma.

show abstract

“…In the literature, few cases of primary CNS ALCL have been described, but in those cases the tumor-associated mortality seemed to be lower in patients with ALK-positive ALCL and young age [15]. The secondary spread of primary nodal or systemic ALCL to the CNS is a rare event [7][8][9][10][11][12][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

“…Most European pediatric oncology groups have used short-pulse chemotherapy regimens, including high-dose methotrexate (MTX), cyclophosphamide, vincristine, doxorubicin, and corticosteroids with a total duration of 4-6 months [7][8][9][16][17][18]. In the early nineties, like in North America, our group treated patients with ALCL with prolonged, repeated-pulse chemotherapy, based on a modified LSA-L2 protocol [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Results of AIEOP LNH‐97 protocol for the treatment of anaplastic large cell lymphoma of childhood

Pillon

Gregucci

Lombardi

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundAnaplastic large cell lymphoma (ALCL) represents approximately 15% of all pediatric non‐Hodgkin lymphomas (NHL). It has distinct clinical features, including frequent involvement of extranodal sites and rare localization to the central nervous system (CNS). Despite varying treatment approaches the outcome of patients with ALCL has not significantly improved during the last two decades.ProcedureFrom October 1997 to beginning of 2000, newly diagnosed ALCL patients were enrolled into AIEOP LNH‐97 protocol for ALCL. Thereafter and until 2007, only CNS positive patients were included. AIEOP LNH‐97 was based on the BFM‐95 schema for ALCL and included six high‐dose chemotherapy courses. CNS prophylaxis was obtained with one intrathecal injection of chemotherapy in each course, whereas treatment of CNS involvement included three intrathecal injections without irradiation.ResultsThirty‐two patients were eligible for the study. Lymph‐node disease was the most frequent localization (69% of the cases), followed by mediastinal (25%), CNS (22%), bone marrow (16%), and skin (13%) involvement. Probabilities of overall survival (OS) and of event‐free survival (EFS) at 5 years for the whole population were 87% (SE 6%) and 68% (SE 8%), respectively.ConclusionsThis study confirmed that short pulse chemotherapy is an efficacious treatment option for first line therapy of pediatric ALCL, and that dose intensity may have some relevance for outcome, but not in all of the patients. Refinement and optimization of therapy strategies for ALCL may originate from a combination of clinical and biological prospective studies, as those in the pipeline of current international collaboration. Pediatr Blood Cancer 2012; 59: 828–833. © 2012 Wiley Periodicals, Inc.

show abstract

Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies.

Abstract: Short-pulse chemotherapy over 2 to 5 months without local therapy modalities is effective in the treatment of Ki-1 ALCL.

Cited by 188 publications

References 37 publications

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

Stem cell transplantation for pediatric lymphoma: past, present and future

Results of AIEOP LNH‐97 protocol for the treatment of anaplastic large cell lymphoma of childhood

Contact Info

Product

Resources

About